Participated · Equity · Mar 2026

Lenoss Medical is a growth-stage biomedical company headquartered in Providence, RI, focused on biological solutions for physiological repair of skeletal defects. Its flagship platform, OsteoPearl®, is an implant and surgical instrument system designed to enable physicians to place natural bone where additional bone is required in spinal vertebral augmentation procedures. The company reported record sales in the fourth quarter and year-over-year surgical procedure growth of nearly 150%, demonstrating accelerating clinical adoption. Management plans to use new capital to expand commercial coverage by hiring regional sales leadership, to increase clinical data generation, and to scale operations and marketing to support further adoption. The company is led by an experienced team of MedTech professionals and counts multiple venture investors and angels among its backers.

Participated · Seed · Feb 2026

GelMEDIX is building regenerative ophthalmic therapies around a proprietary injectable hydrogel scaffold that is delivered as a liquid and light-activated in situ to form a biocompatible, biodegradable matrix. The platform is engineered to protect transplanted cells during injection, localize them at the target site, and promote integration and tissue regeneration, thereby improving the safety and efficacy of cell and gene therapies. Its lead candidate, GMX-101, combines the scaffold with iPSC-derived retinal pigment epithelial cells to replace damaged tissue and halt disease progression in late-stage Geographic Atrophy; preclinical studies have shown improved cell survival, engraftment, and vision preservation. Beyond internal programs, GelMEDIX has signed its first strategic collaboration with a global pharmaceutical company that will pair the scaffold with multiple stem cell lines to create new cell therapies. Proceeds from the recent $13 million seed round will fund advancement of GMX-101 toward the clinic and further validation of the hydrogel platform. The company also added MIT Professor Michael J. Cima and Safar Partners’ Parinaz Motamedy to its board, reinforcing technical and investor support.

Participated · Seed · Mar 2025

Surgicure Technologies develops medical devices to improve airway management and patient safety, with a patented flagship product called the Horseshoe. The Horseshoe is designed to provide more reliable endotracheal (ET) tube securement, prevent facial pressure injuries, and enable more effective oral care. The technology was originally invented by army respiratory therapists and redesigned by founder Irena King. Surgicure targets clinical settings such as critical care, burn/trauma care, and patient evacuation or transport where improved securement and streamlined workflows can reduce adverse events. The company is female-owned and was founded in 2019; it is working to commercialize its solution and scale adoption across diverse medical environments. Surgicure recently closed a financing round to support commercialization efforts.

Participated · Seed · Apr 2024

Juniper Biomedical is developing a precision, low-power neuromodulation micro-implant platform aimed at treating pelvic health conditions such as urinary and bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders. The company's first application targets long-term therapy for mixed urinary incontinence (MUI), a condition that affects nearly one in three women. Juniper says it has accelerated development and achieved several important preclinical and clinical milestones. The company will use new capital to complete development and commercialization milestones and to fuel expansion plans. Financially, Juniper completed an oversubscribed $2M Series Seed financing and was awarded a $1M NIH SPARC Neuromod Prize to support its work. The team intends to leverage these funds to advance its platform across multiple pelvic health care gaps.

Participated · Seed · Jan 2022

Theromics Inc. develops injectable nanopolymer gels, including its flagship HeatSYNC and CryoSYNC products, that enhance energy-directed soft-tissue ablation and enable localized drug delivery. The company's HeatSYNC nanogel is designed to augment ablation energy and allow controlled, drug-infused combination therapy with potentially fewer systemic side effects. Theromics plans to submit its products to the FDA this year with commercialization expected to begin in 2025. The company received a $1M STTR Phase II grant from the National Science Foundation to support Phase II studies of HeatSYNC focused on safety, performance, and computer modeling of energy-augmentation effects. Phase II work will be led by Chief Science Officer William Park with investigators at Brown University, Dartmouth College, and Kansas State University and will include a chronic safety study as a critical step toward FDA clearance. Founded in 2016 at Brown University and based in West Bridgewater, Massachusetts, Theromics is pursuing applications in targeted drug delivery, women's health, and orthopedic nerve ablation for chronic pain relief and recently added Dr. Bruce B. Lee to its advisory board to guide its women's health effort. Theromics develops a proprietary thermal accelerant gel called HeatSYNC™ designed to optimize and augment soft tissue thermal ablations. HeatSYNC™ is based on a protein naturally found in the body and is intended to improve focus and patient-centric delivery during ablation procedures. The company is initially targeting tumor ablations and plans to expand into applications including pain and abnormal uterine bleeding. Longer-term plans include using the thermal technology as an oncolytic intratumoral drug/immunotherapy delivery platform to potentially enhance efficacy and safety profiles of approved medicines. Theromics is led by CEO Ronald Murphy and has added John L. Brooks III to its Board of Directors. The company is advancing FDA-required testing and preclinical/clinical studies at institutions including Dartmouth College, Brown University, Purdue University, and Kansas State University.